|
JP2018076368A
|
|
Combinations of hepatitis c virus inhibitors
|
|
AU2014305090A1
|
|
Injection aid for use with an injection device and method of use
|
|
JP2014156472A
|
|
QUINUCLIDINE COMPOUNDS AS α-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
|
|
JP2007181703A
|
|
Sealing for controlled evacuation ostomy appliance
|
|
CN101356161A
|
|
Heterocyclic CETP inhibitors
|
|
CN101321751A
|
|
Met kinase inhibitors
|
|
CN101312977A
|
|
Fused heterocyclic compounds useful as kinase modulators
|
|
CN101238128A
|
|
Azabicyclic heterocycles as cannabinoid receptor modulators
|
|
CN101193889A
|
|
Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehyftogenase type I
|
|
CN101198253A
|
|
Combinations, methods and compositions for treating cancer
|
|
BRPI0608144A2
|
|
use of a mutant ctla4 molecule
|
|
US2006154962A1
|
|
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
US2006154973A1
|
|
Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
|
JP2007159416A
|
|
Discrimination of tolerance to dasatinib and method for overcoming same tolerance
|
|
CN101065380A
|
|
Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
|
|
US2006030708A1
|
|
Methods for the preparation of pyrrolotriazine compounds
|
|
US2006019364A1
|
|
Acetyl CoA carboxylase 2 sequences and methods
|
|
RU2387655C2
|
|
Hepatitis c virus replication inhibitor
|
|
US2006004222A1
|
|
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
|
CN101006063A
|
|
Five-membered heterocycles useful as serine protease inhibitors.
|
